Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesApollomics Inc. Class A Ordinary Shares

Apollomics Inc. Class A Ordinary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
19.0 USD 2.02 ( 11.90%)
Last update at 2026-11-06T21:00:00Z
VOLUME
14019
Market Cap
29.05M

Momentum Score

…

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
18.65
Low
19.77
High
52 Week Price Range
3.66
Low
40.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Apollomics Inc. is a clinical-stage biopharmaceutical company developing oncology therapies for the Chinese and global markets. Long-term growth drivers include clinical trial progression, regulatory approvals, and partnerships or licensing that could support commercialization of advancing candidates.

Primary investment risks are high clinical and regulatory execution risk, reliance on a small number of development-stage assets, ongoing need for external financing, and intense competition from larger oncology drug developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.98
Dividend Yield
-
Revenue TTM
6.93M
Revenue Per Share
6.29
Gross Profit TTM
6.93M
Debt / Equity
0.20
ROE
-380.13%
Net Debt
-8.80M
ROCE
-721.65%
Diluted EPS TTM
-26.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -53.60M -172.59M -240.81M -94.80M -74.91M
Net income -53.86M -172.60M -240.81M -94.80M -74.82M
Selling general administrative 17.77M 20.64M 9.95M 15.29M 11.04M
Gross profit 0.20M 0.82M - - -
Reconciled depreciation 0.36M 0.67M 0.78M 0.68M 0.61M
Ebit -41.13M -53.55M -240.21M -91.75M -74.08M
Ebitda -41.05M -53.45M -239.44M -91.07M -73.48M
Depreciation and amortization 0.07M 0.10M 0.78M 0.68M 0.61M
Operating income -42.14M -54.01M -240.21M -91.75M -74.08M
Other operating expenses 42.33M 54.83M 44.39M 50.27M 40.75M
Interest expense 0.18M 0.15M 0.09M 0.08M 0.07M
Tax provision 0.26M 0.01M 0.00M 0.00M -0.09M
Interest income 0.48M 0.75M 0.43M 0.47M 0.33M
Net interest income 0.30M 0.60M 0.34M 0.38M -3.52M
Income tax expense 0.26M 0.01M 0.00M 0.00M -0.09M
Total revenue 0.20M 0.82M 0.00M 0.00M 0.00M
Total operating expenses 42.33M 54.83M 44.39M 50.27M 40.75M
Cost of revenue 0.36M 0.69M - - -
Total other income expense net -11.46M -118.58M -196.76M -44.91M -30.63M
Net income from continuing ops -53.86M -172.60M -240.81M -94.80M -74.82M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 13.10M 55.39M 76.47M 123.44M 169.94M
Intangible assets 1.74M 14.76M 14.78M 14.80M 10.32M
Other current assets 0.37M - - - -
Total liab 8.23M 14.15M 524.60M 336.30M 297.87M
Total stockholder equity 4.86M 41.23M -448.12M -212.86M -127.93M
Other current liab 7.17M 9.16M 11.74M 13.05M 11.57M
Common stock 0.01M 0.01M 0.04M 0.04M 0.04M
Capital stock 0.01M 0.01M 0.04M 0.04M 0.04M
Retained earnings -700.82M -646.97M -474.60M -235.44M -141.54M
Cash 9.77M 32.06M 32.67M 46.74M 130.65M
Total current liabilities 7.40M 13.56M 12.36M 13.56M 12.08M
Net debt -8.80M -27.39M -31.68M -45.70M -129.13M
Short term debt 0.23M 4.39M 0.61M 0.51M 0.51M
Short long term debt - 4.24M - - -
Short long term debt total 0.97M 4.66M 0.99M 1.04M 1.51M
Other stockholder equity 702.24M 684.75M 23.04M 10.24M 8.50M
Total current assets 10.27M 39.92M 55.79M 99.37M 157.66M
Long term investments - 0.00M 4.31M 7.84M 0.00M
Short term investments 0.01M 5.76M 21.94M 47.74M 23.74M
Net receivables 0.13M 0.47M 0.55M 0.51M 0.41M
Accumulated other comprehensive income 3.44M 3.44M 3.40M 12.29M 5.08M
Non currrent assets other 0.07M 0.12M 0.12M 0.11M 0.09M
Non current assets total 2.83M 15.46M 20.68M 24.07M 12.28M
Capital lease obligations 0.97M 0.42M 0.99M 1.04M 1.51M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 5.98M 21.36M 29.05M -38.95M 2.33M
Total cashflows from investing activities 5.98M 21.36M - - -
Net borrowings 0.66M 24.04M - - -
Total cash from financing activities 0.47M 21.23M -0.29M -1.64M 125.51M
Net income -53.86M -172.60M -240.81M -94.80M -74.91M
Change in cash -22.29M -0.62M -14.06M -83.91M 92.16M
Begin period cash flow 32.06M 32.67M 46.74M 130.65M 38.49M
End period cash flow 9.77M 32.06M 32.67M 46.74M 130.65M
Total cash from operating activities -28.74M -43.21M -42.82M -43.31M -35.68M
Issuance of capital stock - - 0.39M 0.14M 6.03M
Depreciation 0.36M 0.67M 0.78M 0.68M 0.61M
Other cashflows from investing activities 6.01M 21.37M - - -
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Other cashflows from financing activities -4.41M 4.11M -0.09M -1.26M 119.96M
Capital expenditures 0.02M 0.01M 0.37M 7.55M 10.14M
Change in working capital 1.61M -0.93M 6.49M 2.64M 3.06M
Stock based compensation 10.93M 12.69M 3.58M 8.12M 4.51M
Other non cash items 12.22M 116.97M 187.14M 40.04M 31.04M
Free cash flow -28.77M -43.22M -43.19M -50.86M -45.83M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
APLM
Apollomics Inc. Class A Ordinary Shares		 2.02
11.90%		 19.00 - - 4.19 8.15 3.35 -0.10
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Apollomics Inc. Class A Ordinary Shares

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

989 East Hillsdale Blvd., Foster City, CA, United States, 94404

650 209 4055

https://www.apollomicsinc.com

13

Name Title Year Born
Dr. Guo-Liang Yu Ph.D. Co-Founder, CEO & Executive Chairman 1963
Dr. Sanjeev Redkar MBA, Ph.D. Co-Founder, President & Executive Director 1969
Dr. Matthew James Plunkett Ph.D. Chief Financial Officer 1972
Dr. Kin-Hung Yu M.D. Chief Medical Officer 1962
Dr. Chinglin Lai Ph.D. Senior Vice President of Biostatistics & Data Management NA
Mr. Hung-Wen Chen CEO & Chairman of the Board 1962
Mr. K. H. Lin C.A.I.A., M.B.A. Chief Financial Officer 1970
Mr. Yi-Kuei Chen Director & COO 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…